Glenmark Pharma will declare its third quarter (October-December) earnings today. According to CNBC-TV18 poll, analysts expect profit after tax of the company to fall 14 percent year-on-year to Rs 184 crore.
The growth in numbers is expected to moderate on yearly basis because it comes on a high base. In a year ago period (Q3FY13), the company had reported licensing income of Rs 49.3 crore that boosted earnings. Revenues jumped 34 percent to Rs 1,382 crore and EBITDA grew 211 percent to Rs 320 crore.
Revenues are seen going up 13.2 percent to Rs 1,565 crore in the quarter ended December 2013 from Rs 1,382 crore in a year ago period.
Operating profit or earnings before interest, tax, depreciation and amortisation may grow 5.6 percent to Rs 338 crore and operating profit margin may drop 160 basis points to 21.6 percent compared to same quarter last year.
The full year (FY14) guidance is 20 percent growth on sales and margin at 21 percent.
Analysts believe, the segment wise generics are expected to lead with an over 25 percent growth and specialities at over 15 percent.
They expect continued momentum in the US and India. Indian business grew 21 percent despite trade issues in Q2 that was much ahead of industry. Hence the management expects 18-20 percent growth in India going forward. US revenues jumped 30 percent year-on-year.
The pick up in rest of the world markets, which dropped 10 percent in Q2 Y-o-Y and Russian business, which was expected to pick up in October-March FY14 due to onset of winter, will be closely watched by analysts.
Mexico and Venenzuela businesses are expected to continue showing growth. Glenmak guided for 22-25 percent FY14 growth in Venenzuela business.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
